Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guanosine-2',3'-cyclophosphorothioate is a synthetic cyclic guanosine monophosphorothioate, a nucleotide analogue where a sulfur atom replaces one of the oxygen atoms in the phosphate group, and the phosphate forms a cyclic linkage between the 2' and 3' hydroxyls of the ribose sugar. This phosphorothioate modification typically confers resistance to enzymatic degradation by phosphodiesterases. While specific therapeutic applications for this exact compound are not widely documented, it is primarily used as a laboratory reagent for biochemical research. Related cyclic guanosine monophosphorothioate analogues (often 3',5'-cyclic forms) are known to modulate cGMP signaling pathways, for instance, by inhibiting protein kinase G (PKG).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Guanosine-2',3'-cyclophosphorothioate.